Higher ECOG performance status at start of therapy, negative HR-status, lack of HER2 overexpression, high tumor grade, high tumor stage at initial diagnosis, and metastatic sites other than bone-only (liver, peritoneum, other visceral or non-visceral) were all independently associated with a worse prognosis. The gene discussed is ERBB2; the disease is neoplasm.